Nitric oxide (NO) is a simple heterodiatomic molecule with a broad range of biologic actions. In the cardiovascular system NO serves as an endothelium-dependent vasodilator, an antithrombotic agent, an antiproliferative molecule, and a regulator of cardiac contractility. Owing to its reactivity under physiologic conditions, accumulating data suggest that NO forms derivatives with several classes of biologic compounds. One group of biochemical functionalities that serves this role is that of thiols, which can form thionitrites or S-nitrosothiols with NO. In this paper we will examine the effects of the biologically known and the chemically produced S-nitrosothiols on the cardiovascular system in order to understand better what role these compounds may play in physiologic and pathologic states.
StuehrD JGriffithO W. Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol1992; 65: 287–346.
2.
WelchG NLoscalzoJ. Nitric oxide and the cardiovascular system. J Cardiac Surg1994; 9: 361–71.
3.
MuradFArnoldW PMittalC KBrughlerJ M. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Adv Cyclic Nucleotide Res1979; 11: 175–204.
4.
BredtD SSnyderS H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA1990; 87: 682–85.
5.
DrapierJ CHibbsJ B. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol1988; 140: 2829–38.
6.
StuehrD JMarietaM A. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines or interferon gamma. J Immunol1987; 139: 518–25.
7.
DingA HNathanC FStuehrD J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J Immunol1988; 141: 2407–12.
8.
NathanC. Nitric oxide as a secondary product of mammalian cells. FASEB J1992; 6: 3051–64.
9.
MillsC D. Molecular suppression of ‘suppressor’ macrophages. J Immunol1991; 146: 2719–23.
10.
IgnarroL JLiptonHEdwardsJ C. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther1981; 218: 739–49.
11.
IgnarroL J. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension1990; 16: 477–83.
12.
FurchgottR FZawadzkiJ V. The obligatory role of endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature1980; 288: 373–76.
13.
RiddJ H. Nitrosation. In: WilliamsD C, ed. Advances in physical and organic chemistry, volume 16. New York: Cambridge University Press, 1978: 1–214.
14.
OaeSTukushineDKimY H. Novel method of activating thiols by their conversion into thionitrites with dinitrogen tetroxide. J Chem Soc Chem Commun1977; 407.
15.
SavilleB. A scheme for colorimetric determination of microgram amounts of thiols. Analyst1958; 83: 670–72.
16.
IgnarroL JGruetterC A. Requirement of thiols for activation of coronary artery guanylate cyclase by glyceryl trinitrate and sodium nitrite: Possible involvement of S-nitrosothiols. Biochim Biophys Acta1980; 631: 221–31.
17.
StamlerJ SSimonD IOsborneJ A. S-Nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA1992; 89: 444–48.
18.
IgnarroL J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res1989; 65: 1–21.
19.
StamlerJ SJarakiOOsborneJ. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA1992; 89: 7674–77.
20.
StamlerJ SSingelD JLoscalzoJ. Biochemistry of nitric oxide and its redox-activated forms. Science1992; 258: 1898–902.
21.
WilliamsD L H. S-Nitrosation and the reactions of S-nitroso-compounds. Chem Soc Rev1985; 14: 171–96.
22.
GirardPPtierP. NO, thiols and disulfides. FEBS Lett1993; 320: 7–8.
23.
FieldLDiltsR VRavichandranBLenhartP GCarnahanG E. An unusually stable thionitrite from N-acetyl-D,L-penicillamine; x-ray crystal and molecular structure of 2-(acetylamino)-2-carboxy-1,1-dimethylethyl thionitrite. J Chem Soc Perkin Trans I, 1978; 249–50.
24.
ParkJ W. Reaction of S-nitrosoglutathione with sulfhydryl groups in protein. Biochem Biophys Res Commun1988; 152: 916–20.
25.
KharitonovV GSundquistA RSharmaV S. Kinetics of nitrosation of thiols by nitric oxide in the prescence of oxygen. J Biol Chem1995; 270: 28158–64.
26.
MatthewsW RKerrS W. Biological activity of S-nitrosothiols: The role of nitric oxide. J Pharmacol Exp Ther1993; 267: 1529–37.
27.
NewmanC MWarrenJ BTaylorG WBoebisA RDaviesD S. Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: Prevention by N-acetyl-L- but not N-acetyl-D-cysteine. Br J Pharmacol1990; 99: 825–29.
28.
BatesN JBakerM TGuerraRHarrisonD G. Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol1991; 42 (suppl): S157–65.
29.
IgnarroL JBarryB KGruetterD V. Selective alterations in responsiveness of guanylate cyclase to activation by nitroso compounds during enzyme purification. Biochim Biophys Acta1981; 673: 394–407.
30.
WuX BBruneBVon AppenFUllrichV. Reversible activation of soluble guanylate cyclase by oxidizing agents. Arch Biochem Biophys1992; 294: 75–82.
31.
IgnarroL JGruetterC AHymanA LKadowitzP J. Molecular mechanisms of vasodilation. In: PosteGCrookeS T, eds. Dopamine receptor agonists. New York: Plenum Press, 1984; 259–88.
32.
FeelischMNoackE A. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol1987; 139: 19–30.
33.
FeelischMNoackESchroderH. Explanation of the discrepancy between the degree of organic nitrate decomposition, nitrite formation and guanylate cyclase stimulation. Eur Heart J1989; 9 (suppl A): 57–62.
34.
MurphyM EPiperH MWatanabeHSiesH. Nitric oxide production by cultured aortic endothelial cells in response to thiol depletion and replenishment. J Biol Chem1991; 286: 19378–83.
35.
HenryP JDrummerO HHorowitzJ D. S-Nitrosothiols as vasodilators: Implications regarding tolerance to nitric oxide-containing vasodilators. Br J Pharmacol1989; 98: 757–66.
36.
FungH LKowalukC EHoughKKakemiM. Mechanisms for the pharmacologic interaction of organic nitrates with thiols. Existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther1988; 245: 524–30.
37.
IgnarroL JKadowitzP JBaricosW H. Evidence that regulation of hepatic guanylate cyclase activity involves interactions between catalytic site SH groups and both substrate and activator. Arch Biochem Biophys1981; 208: 75–86.
38.
StamlerJ SLoscalzoJ. Capillary zone electrophoretic detection of biological thiols and their S-nitrosated derivatives. Anal Chem1992; 64: 779–85.
39.
ScharfsteinJ SKeaneyJSlivkaA. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest1994; 94: 1432–39.
40.
RubanyiG MRomeroJ CVanhoutteP M. Flow-induced release of endothelium-dependent relaxation factor. Am J Physiol1986; 250: H1145–49.
41.
CookeJ PStamlerJ SAndonNMcKinleyGLoscalzoJ. Flow-mediated endothelium-dependent vasodilation is potentiated by N-acetylcysteine. Am J Physiol1990; 28: H804–H12.
42.
CookeJ PRossitchEJrAndonNLoscalzoJDzauV J. Flow activates a specific endothelium potassium channel to release an endogenous vasodilator. J Clin Invest1991; 88: 1663–71.
KeaneyJSimonD IStamlerJ S. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest1993; 91: 1582–89.
47.
SiegfriedM RCareyCXin-LiangXLeferA M. Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am J Physiol1992; 32: H771–77.
48.
HareJ MKeaneyJ FJrBalligandJ L. Role of nitric oxide in sympathetic parasympathetic modulation of myocardial contractility in normal dogs. J Clin Invest1995; 95: 360–66.
49.
BauerJ AFungH L. Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure. J Pharmacol Exp Ther1991; 256: 249–54.
50.
SynekPRusanekKSpanovaHMlenjnkovaM. The effect of ethanol and nitroglycerin on platelet aggregation. Act Nerv1970; 12: 77–82.
51.
HamptonJ RHarrisonA JHonourA JMitchellJ R. Platelet behavior and drugs used in cardiovascular disease. Cardiovasc Res1967; 1: 101–106.
52.
MellionB TIgnarroL JOhlsteinE HPontecorvoE GHymanA LKadowitzP J. Evidence for the inhibitory role of guanosine 3',5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related nitrovasodilators. Blood1981; 57: 946–55.
53.
StamlerJCunninghamMLoscalzoJ. Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation. Am J Cardiol1988; 62: 377–80.
54.
MellionB TIgnarroL JMyersC B. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate-cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol1983; 23: 653–64.
55.
LoscalzoJ. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest1985; 76: 703–708.
56.
LoscalzoJFreedmanJ E. Purification and characterization of human platelet glutathione-S-transferase. Blood1986; 67: 1595–99.
57.
MendelsohnMO'NeillSGeorgeDLoscalzoJ. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem1990; 265: 19028–34.
58.
LiebermanE HO'NeillSMendelsohnM. S-Nitrosocysteine inhibits human platelet secretion by a cyclic GMP-mediated mechanism. Circ Res1991; 68: 1722–28.
59.
KeaneyJ FSimonD IStamlerJ S. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest1993; 91: 1582–89.
60.
KeaneyJ FStamlerJ SScharfsteinJ SLoscalzoJ. NO forms a stable adduct with serum albumin that has potent antiplatelet properties in vivo. Clin Res1992; 40: 194a.
61.
StamlerJ SVaughanD ELoscalzoJ. Synergistic disaggregation of platelets by tissue plasminogen activator, prostaglandin E, and nitroglycerin. Circ Res1989; 65: 796–804.
62.
RadiRBeckmanJ SBushK MFreemanB A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem1991; 266: 4244–50.
63.
ClarkR LDalyKRobinsonE. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med1991; 324: 1149–55.
64.
ManilowM R. Hyperhomocyst(e)inemia: A common and easily reversible risk factor for occlusive atherosclerosis. Circulation1990; 81: 1149–55.
65.
KangS SWongP W KCookH YNorusisMMesserJ V. Protein-bound homocyst(e)ine: A possible risk factor for coronary artery disease. J Clin Invest1986; 77: 1482–86.
66.
RefsumHHellandSUelandP M. Radioenzymatic determination of homocysteine in plasma and urine. Clin Chem1985; 31: 624–28.
67.
SpindelEMcCullyK S. Conversion of methionine to homocysteine thiolactone in liver. Biochim Biophys Acta1974; 343: 687–91.
68.
McCullyK S. Homocysteine metabolism in scurvy, growth and atherosclerosis. Nature1971; 231: 391–92.
69.
StamlerJ SOsborneJ AJarakiO. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest1993; 91: 308–18.
70.
JiaLFurchgottR F. Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther1993; 267: 371–78.
71.
GastonBReillyJDrazenJ M. Endogenous nitric oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA1993; 90: 10956–61.
72.
LoscalzoJ. Endothelial dysfunction in pulmonary hypertension. N Engl J Med1992; 327: 117–19.
73.
LiuS FCrawleyD EBarnesP JEvansT W. Endothelium-derived relaxing factor inhibits hypoxic pulmonary vasoconstriction in rats. Am Rev Resp Dis1991. 143: 32–37.
74.
Pepke-ZabaJHiggenbottamT WXuanDinh A TStoneDWallworkJ. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet1991; 338: 1173–74.
75.
RobertsJ DJrLangPBigatelloL MVlahakesG JZapolW M. Inhaled nitric oxide in congenital heart disease. Circulation1993; 87: 447–53.
76.
RossaintRFalkeK JLopezFSlamaKPisonUZapolW M. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med1993; 328: 399–400.
77.
LohEStamlerJ SHareJ MLoscalzoJColucciW S. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation1994; 90: 2780–85.
78.
FoltsJ DStamlerJ SKeaneyJJrLoscalzoJ. Coating stenosed intimally damaged dog coronary arteries with S-nitrosated albumin prevents platelet adhesion-aggregation and thrombus formation. Circulation1994; 90: 1–345.
79.
MarksD SVitaJ AFoltsJ DKeaneyJ FJrWelchG NLoscalzoJ. Inhibition of neointimal proliferation in rabbits following vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest1995; 96: 2630–38.
80.
FreedmanJ FFabianALoscalzoJ. Impaired release of EDRF by cultured endothelial cells after exposure to fibrin monomer and fibrin(ogen) degradation products. Am J Physiol (in press).
81.
PanzaJ AQuyyuniA ABrushJ EJrEpsteinS E. Abnormal endothelial-dependent vasorelaxation in patients with essential hypertension. N Engl J Med1990; 323: 22–27.
82.
LoscalzoJSmickDAndonNCookeJ. S-Nitrosocaptopril. 1. Molecular characterization and effects on the vasculature and on platelets. J Pharmacol Exp Ther1989; 249: 726–29.
83.
SchafferJ ELeeFThompsonSHanBCookeJLoscalzoJ. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J Pharmacol Exp Ther1991; 256: 704–709.
84.
SalveminiDPistelliAMollaceV. Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: In vitro and in vivo studies. Br J Pharmacol1993; 109: 430–36.
85.
GoldschmidtJ ETallaridaR J. Pharmacological evidence that captopril possesses an endothelium-derived relaxing factor properties. J Pharmacol Exp Ther1991; 257: 1136–45.
86.
KannerJ. S-Nitrosocysteine (RSNO), an effective antioxidant in cured meat. J Am Oil Chem Soc1978; 56: 74–76.
87.
KannerJ. S-Nitrosocysteine as an antioxidant, color-developing, and anticlostridial agent in comminuted turkey meat. J Food Sci1980; 45: 1105–106.
88.
ArnoldW PMittalC KKatsukiSMuradF. Nitric oxide activates guanylate cyclase and increases guanosine 3',5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA1977; 74: 3203–207.
89.
KilboumR GJurbanAGrossSGriffithO WFeldmanP LWisemanJ. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun1990; 172: 1132–38.
KoshidaHKotakeY. Nitric oxide does not contribute to superoxidemediated sulfhydryl oxidation in human polymorphonuclear leukocytes. Life Sci1994; 6: 743–70.
